← Back to Search

Other

A Prospective Study of EUS Guided Celiac Block

N/A
Waitlist Available
Led By Julia LeBlanc, MD, MPH
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

The purpose of this prospective study is to measure the clinical effectiveness of EUS-guided CB in subjects, 50 who have chronic pancreatitis and 50 who have pancreatic cancer, that are already undergoing celiac block for clinical reasons.

Eligible Conditions
  • Pancreatic Cancer
  • Chronic Pancreatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: 2Experimental Treatment1 Intervention
subjects who are getting a celiac block for pancreatic cancer
Group II: 1Experimental Treatment1 Intervention
subjects who are getting a celiac block for chronic pancreatitis
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Triamcinolone
FDA approved
Ethanol
FDA approved

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
1,040 Previous Clinical Trials
1,219,937 Total Patients Enrolled
Julia LeBlanc, MD, MPHPrincipal InvestigatorIndiana University
6 Previous Clinical Trials
480 Total Patients Enrolled
~5 spots leftby Dec 2025